youtube_live
Q3 2026 earnings • 3:00 PM tomorrow
See detailschevron_right
ALKS:NASDAQ
Alkermes Plc
$44.79
arrow_downward
-1.21%(-0.55) 1D
Nov 2, 3:02:13 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$45.59
High
$45.94
Low
$44.48
Mkt. cap
7.53B
Avg. vol.
2.14M
Volume
766.65K
P/E ratio
116.60
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
Open
$45.59
High
$45.94
Low
$44.48
Mkt. cap
7.53B
Avg. vol.
2.14M
Volume
766.65K
P/E ratio
116.60
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
Investing.com
·
4 hours ago
Alkermes set to report earnings amid orexin drug pipeline push
Benzinga
·
8 hours ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Dealroom
·
2 days ago
Alkermes starts Phase 2 trial of ALKS 7290 in major depressive disorder
Yahoo Finance
·
2 days ago
Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In?
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com